Navigation Links
JCI table of contents: Oct. 19, 2009
Date:10/19/2009

EDITOR'S PICK: The protein APC slows Lou Gehrig's disease in mice

Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a neurodegenerative disease that causes progressive weakness, disability, and death. Treatments are largely palliative. Using mice carrying the mutated form of the human SOD1 gene that causes inherited forms of ALS, however, Berislav Zlokovic and colleagues, at the University of Rochester Medical Center, Rochester, have now found that administration of the protein APC slows disease progression and extends survival. The authors therefore suggest that strategies designed to activate APC might be of benefit to patients with inherited, and possibly sporadic, ALS. However, in an accompanying commentary, Charles Esmon and Jonathan Glass warn that such an approach would not be without risks.

In the study, administration of both APC, whose main function is to prevent blood clotting, and APC analogs with a reduced ability to prevent blood clotting slowed disease progression in the mutant SOD1expressing mice and extended their survival, even when the compounds were administered after disease onset. Further analysis indicated that these compounds were able to access the brain and that once there, they worked by decreasing expression of the mutant SOD1 in several cell types in the brain, including the nerve cells destroyed in individuals with ALS. This study therefore indicates that APC can have a neuroprotective effect in mouse models of inherited ALS.

TITLE: Activated protein C therapy slows ALS-like disease in mice by transcriptionally inhibiting SOD1 in motor neurons and microglia cells

AUTHOR CONTACT:
Berislav V. Zlokovic
University of Rochester Medical Center, Rochester, New York, USA.
Phone: (585) 273-3132; Fax: (585) 273-3133; E-mail: berislav_zlokovic@urmc.rochester.edu.

View this article at: http://www.jci.org/articles/view/38476?key=6a5479a67edd727312aa

ACCOMPANYING COMMENTARY
TITLE: The APCs of neuroprotection

AUTHOR CONTACT:
Charles T. Esmon
Oklahoma Medical Research Foundation, Oklahoma City, Oklahoma, USA.
Phone: (405) 271-6474; Fax: (405) 271-2872; E-mail: Charles-Esmon@omrf.org.

View the PDF of this article at: https://www.the-jci.org/article.php?id=40682


VASCULAR BIOLOGY: Too much of the protein building block homocysteine inhibits blood vessel formation

TITLE: Homocysteine inhibits neoangiogenesis in mice through blockade of annexin A2dependent fibrinolysis

AUTHOR CONTACT:
Katherine A. Hajjar
Weill Cornell Medical College, New York, New York, USA.
Phone: (212) 746-2034; Fax: (212) 746-8809; E-mail: khajjar@med.cornell.edu.

View this article at: http://www.jci.org/articles/view/39591?key=5eb08d461852e7429305

ACCOMPANYING COMMENTARY
TITLE: Homocysteine-mediated thrombosis and angiostasis in vascular pathobiology

AUTHOR CONTACT:
Joseph Loscalzo
Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.
Phone: (617) 732-6340; Fax: (617) 732-6439; E-mail: jloscalzo@partners.org.

View the PDF of this article at: https://www.the-jci.org/article.php?id=40924


ONCOLOGY: Loss of the protein Smad4 associated with head and neck cancer

TITLE: Smad4 loss in mice causes spontaneous head and neck cancer with increased genomic instability and inflammation

AUTHOR CONTACT:
Shi-Long Lu
University of Colorado Denver, Aurora, Colorado, USA.
Phone: (303) 724-0784; Fax: (303) 724-4553; E-mail: shi-long.lu@ucdenver.edu.

Xiao-Jing Wang
University of Colorado Denver, Aurora, Colorado, USA.
Phone: (303) 724-3001; Fax: (303) 724-4730; E-mail: xj.wang@ucdenver.edu.

View this article at: http://www.jci.org/articles/view/38854?key=fc4a2214d5fa7fb45183

ACCOMPANYING COMMENTARY
TITLE: Smad4: gatekeeper gene in head and neck squamous cell carcinoma

AUTHOR CONTACT:
Murray Korc
Dartmouth-Hitchcock Medical Center, Lebanon, New Hampshire, USA.
Phone: (603) 650-7936; Fax: (603) 650-6122; E-mail: murray.korc@dartmouth.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=41230


NEPHROLOGY: ARH: another link in the molecular chain regulating potassium levels

TITLE: The ARH adaptor protein regulates endocytosis of the ROMK potassium secretory channel in mouse kidney

AUTHOR CONTACT:
Paul A. Welling
University of Maryland School of Medicine, Baltimore, Maryland, USA.
Phone: (410) 706-3851; Fax: (410) 706-8341; E-mail: pwelling@umaryland.edu.

View this article at: http://www.jci.org/articles/view/37950?key=eba726374c485034e543


'/>"/>

Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. Detecting the undetectable in prostate cancer screening
2. Drugs for Irritable Bowel Might Increase Cancer Risk
3. Not Getting Enough Fruits and Vegetables? Think Frozen! Antioxidant-rich Frozen Wild Blueberries are Convenient and Just As Nutritious As Fresh
4. Fabled vegetable lamb plant contains potential treatment for osteoporosis
5. Over 800 Lives of Domestic Violence Survivors Restored by the American Academy of Cosmetic Dentistry Charitable Foundations Give Back A Smile Program
6. Discrete Reportable Transcription to Populate the EHR/EMR With Physician Dictated Reports
7. Certain Types of Infertility Are Preventable
8. Long-Term Back Pain Not Inevitable, Study Finds
9. New Book Provides Alcoholics with Hope for Stable, Long-Term, Craving-Free Sobriety
10. OAKWORKS Clinician Massage Table Product Line Gets a Green Makeover
11. A New Jersey Anti-Poverty Charity Meets a Crisis of Need with Charitable Giving from Local Paterson, NJ Small Businesses
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/17/2017)... ... February 17, 2017 , ... While EHR data has revolutionized ... an innovative workstation designed to reduce nursing fatigue while enhancing productivity. Based on ... offers a lightweight, highly mobile, multi-functional alternative to the limitations of handheld computing. ...
(Date:2/17/2017)... ... February 17, 2017 , ... ... Feb. 22, 2017 — 1:30 p.m. – 2:30 p.m. ET, http://www.fdanews.com/deviceapproval ... asking before selecting an FDA approval pathway? , How should they evaluate ...
(Date:2/17/2017)... , ... February 17, 2017 , ... ... the HIMSS17 Conference & Exhibition in Orlando, Fla., February 19-23. Visitors to the ... the most widely used electronic patient signatures solution in healthcare . ...
(Date:2/17/2017)... ... 17, 2017 , ... PrideStaff, a national staffing organization, is ... Staffing Industry Analysts' 2017 "Staffing 100 North America" list. , Now in ... to the staffing industry over the last twelve months. Industry insiders and observers ...
(Date:2/17/2017)... (PRWEB) , ... February 17, 2017 , ... ... services and financial planning assistance to families and business owners in and around ... a charity drive to help prevent all forms of domestic violence. , There ...
Breaking Medicine News(10 mins):
(Date:2/16/2017)... , Feb. 16, 2017  Newly published research from ... Institute emphasizes the role a private retailer can play ... The study, published online today in the American ... decision to remove tobacco from all CVS Pharmacy stores ... settings with an even greater impact on those who ...
(Date:2/16/2017)... Summary Provides understanding and access to the allergy partnering ... ... Global Allergy Partnering Terms and Agreements since 2010 report provides understanding ... world,s leading healthcare companies. - Trends in partnering ... by company A-Z, industry sector, stage of development, technology type ...
(Date:2/16/2017)... Research and Markets has announced the addition of the ... Application, Cancer Type, Technology - Forecast to 2025" report to ... ... at a CAGR of around 28.6% over the next decade to ... of the prominent trends that the market is witnessing include increasing ...
Breaking Medicine Technology: